IL-17: A Potential Therapeutic Or Biomarker for Immune and Inflammatory Response

Target Name: Interleukin 17

NCBI ID: P9121

Interleukin 17

Other Name(s): IL-17 | Interleukin 17

IL-17: A Potential Therapeutic Or Biomarker for Immune and Inflammatory Response

Interleukin 17 (IL-17), also known as nonspecified subtype (IL-17), is a cytokine that plays a crucial role in the regulation of immune and inflammatory responses. IL-17 is a member of the interleukin family, which includes several other cytokines that play a vital role in the immune response.

IL-17 is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. It also plays a key role in the regulation of inflammation, both acute and chronic. In addition, IL-17 is involved in the regulation of pain perception and the regulation of sleep-wake cycles.

IL-17 has been shown to have a wide range of therapeutic potential, and is currently being targeted by researchers as a potential drug or biomarker. Several studies have shown that IL-17 has the potential to be a therapeutic agent for a variety of diseases, including cancer, autoimmune diseases, and inflammatory disorders.

One of the key reasons for the potential of IL-17 as a drug or biomarker is its ability to stimulate the production of pro-inflammatory cytokines. These cytokines, such as TNF-alpha, IL-8, and IL-18, are involved in the regulation of inflammation and play a key role in the development of many diseases, including cancer and autoimmune disorders. By stimulating the production of these cytokines, IL-17 has been shown to have the potential to stimulate an inflammatory response, which can be useful for the treatment of certain diseases.

In addition to its potential as a therapeutic agent, IL-17 is also being targeted as a potential biomarker for a variety of diseases. The ability of IL-17 to stimulate the production of pro-inflammatory cytokines makes it an attractive candidate for use as a marker for the severity of certain diseases, such as cancer and autoimmune disorders. In addition, IL-17 has been shown to be involved in the regulation of pain perception and the regulation of sleep-wake cycles, which makes it an attractive candidate for use as a biomarker for pain and sleep disorders.

Despite the potential of IL-17 as a drug or biomarker, much more research is needed to fully understand its role in the immune and inflammatory responses. In addition, the use of IL-17 as a therapeutic agent or biomarker is still in its early stages, and more research is needed to determine its safety and effectiveness.

In conclusion, IL-17 is a cytokine that plays a crucial role in the regulation of immune and inflammatory responses. Its ability to stimulate the production of pro-inflammatory cytokines makes it the potential target of a variety of therapeutic agents, and its potential as a biomarker for the regulation of pain and sleep disorders makes it an attractive candidate for further research. Further research is needed to fully understand the role of IL-17 in the immune and inflammatory responses and to determine its safety and effectiveness as a therapeutic agent or biomarker.

Protein Name: Interleukin 17 (nonspecified Subtype)

The "Interleukin 17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Interleukin 17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets